GF CSI Innovative Drugs Industry ETF(515120) rises 2.49%, aiming for a fourth consecutive gain

NewTimeSpace (newtimespace.com) News, as of 10:48 on June 24, 2026, GF Innovative Drug ETF (515120) rose 2.49%, aiming for a fourth consecutive gain. The latest price was 0.58 yuan. Over a longer time frame, as of June 23, 2026, the ETF accumulated a gain of 4.65% over the past week, ranking 3/7 among comparable funds.

In terms of liquidity, GF Innovative Drug ETF recorded an intraday turnover rate of 5.86% and a trading volume of 558 million yuan. Over a longer time frame, as of June 23, the ETF's average daily trading volume over the past week reached 416 million yuan, ranking in the top 2 among comparable funds.

In terms of scale, GF Innovative Drug ETF saw a significant increase of 374 million yuan in scale over the past week, with the new scale increase ranking 2/7 among comparable funds. (Data source: Wind)

In terms of shares, GF Innovative Drug ETF experienced a significant increase of 25.00 million units in share count month-to-date, with the new share increase ranking 3/7 among comparable funds. (Data source: Wind)

In terms of capital flows, the latest net inflow for GF Innovative Drug ETF was 23.7781 million yuan. Over a longer time frame, within the past 16 trading days, it attracted a total of 148 million yuan in net inflow. (Data source: Wind)

Data shows that leveraged funds are continuously positioning. The latest margin financing purchase amount of GF Innovative Drug ETF reached 52.2795 million yuan, with the latest margin financing balance standing at 354 million yuan. (Data source: Wind)

As of June 23, the net value of GF Innovative Drug ETF rose by 18.69% over the past two years. From the perspective of return capability, as of June 23, 2026, since its inception, the ETF achieved a highest single-month return of 23.00%, a longest streak of consecutive up months of 5 months, a maximum cumulative gain during that streak of 32.68%, and an average return of 5.50% in up months. As of June 23, 2026, the ETF's annualized excess return over its benchmark for the past three months was 2.58%.

In terms of drawdown, as of June 23, 2026, GF Innovative Drug ETF recorded a drawdown of 0.14% relative to its benchmark since the beginning of the year, reflecting lower drawdown risk among comparable funds.

In terms of fees, GF Innovative Drug ETF has a management fee rate of 0.50% and a custodian fee rate of 0.10%.

In terms of tracking accuracy, as of June 23, 2026, the one-year tracking error of GF Innovative Drug ETF was 0.028%, achieving the highest tracking accuracy among comparable funds.

From a valuation perspective, the latest price-to-earnings (PE-TTM) ratio of the CSI Innovative Drug Industry Index, which GF Innovative Drug ETF tracks, is only 42.95 times, standing at the 11.36% percentile over the past year. This means the valuation is lower than over 88.64% of the time in the past year, placing it at a historical low.

GF Innovative Drug ETF closely tracks the CSI Innovative Drug Industry Index. The CSI Innovative Drug Industry Index selects no more than 50 of the most representative listed company securities whose main businesses involve innovative drug research and development as index constituents, in order to reflect the overall performance of the securities of listed companies in the innovative drug industry.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.